about
Isoprinosine versus other antiviral drugs for chronic hepatitis BIsoprinosine for chronic hepatitis BAdefovir dipivoxil versus other antiviral drugs for chronic hepatitis BAdefovir dipivoxil for chronic hepatitis BAdefovir dipivoxil for chronic hepatitis BTelbivudine for chronic hepatitis BBasal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutantsHepatitis B virus: inactive carriersKASL clinical practice guidelines: management of chronic hepatitis BUpdate on Hepatitis B Virus Infection: Focus on TreatmentViral quasispecies evolutionHepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patientsAdvancing patient care: integrating new data.High frequency of the 1896 precore mutation in patients and blood donors with hepatitis B virus infection from the Indian subcontinent.Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48.Hepatitis B Virus Immunopathology, Model Systems, and Current TherapiesTo treat or not to treat the "immunotolerant phase" of hepatitis B infection: A tunnel of controversy.A new model mimicking persistent HBV e antigen-negative infection using covalently closed circular DNA in immunocompetent mice.Development of a molecular-beacon assay to detect the G1896A precore mutation in hepatitis B virus-infected individuals.Current antiviral therapy for chronic hepatitis B.Prevalence of antibody to hepatitis B core antigen among hepatitis B surface antigen-negative blood donors in Ilorin, Nigeria: A cross-sectional studyPrevalence and Characteristics of Precore Mutation in Iran and Its Correlation with Genotypes of Hepatitis B.Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in ItalyHBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection.Mutations in pre-core and basal-core promoter regions of hepatitis B virus in chronic HBV patients from Golestan, Iran.Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study.Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials.Natural history of chronic hepatitis B: phases in a complex relationship.The Role of Interferon in Hepatitis B Therapy.Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates.TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistenceClinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in TaiwanEntecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion.Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance.Current status of antiviral therapy for hepatitis BHepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections.Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype.Hepatitis B viral genotypes: clinical relevance and molecular characteristics.Precore and core promoter mutations of the hepatitis B virus gene in chronic genotype C-infected children.Predictive power of hepatitis B 1762T/1764A mutations in plasma for hepatocellular carcinoma risk in Qidong, China.
P2860
Q24198159-7647B4FA-5455-4487-B9EE-3603C7313AF8Q24198851-2303939E-0B14-4F6F-9A7A-16574668A83EQ24234842-9E7C1160-67C6-4977-A9DF-57F44B0FBF69Q24234931-0C0DAFD5-9BC4-491B-A506-4FC28CCFC57EQ24235209-69C68786-F6D5-4BDC-A5C3-4B4B7342E36AQ24235644-121D6D1E-D799-4AE5-9C3A-C2CF65B808E0Q24563991-CE7A5D68-21FC-43B9-844D-FF3137F8FC4DQ24810833-2DCE5EC0-9D1D-44DA-AE23-75033B7088BFQ26752475-7E5860F9-19A4-4616-8F75-FB52721E70E1Q26781990-6FF05D1F-6374-4D16-8A7F-8DDE8A216A65Q27013917-C9FE7BAF-589A-4976-B6A5-AA695F340705Q27477975-A10E1C0C-36ED-447F-9A4C-0C5C13E7A301Q31031231-CA14AEA7-2824-47AB-8039-54238F3DF7EDQ33204408-073E0091-94EB-4437-98A2-0356BFCB0219Q33549555-E1B17072-E67E-4D87-8CC0-428576942CE6Q33559657-DBD81B38-76CC-47EA-893D-C3968587B317Q33563893-C1092B93-EACD-43ED-8C26-9522E0F0B1ADQ33585283-54896B26-ECD8-4EC7-BE68-4195CB75C6FCQ33592384-B0C770BE-294A-4B3E-8668-21D341EF2B0CQ33631693-C5DEE0F0-94E5-45DC-94FF-AAAC39191503Q33721418-C5CCC0B5-583D-4849-A015-1B1A4898544DQ33764123-18C98E19-DB6B-4996-8F22-858E74D0A4E4Q33801300-338BBD78-3BD9-4A0C-973B-B51FBD935C26Q33801305-83D3473E-6BFA-4FB2-B621-FF7B61FDAE7DQ33802585-08414CBE-9CBF-4287-9A0A-A119E6548C0EQ33879651-3D801516-9235-49E6-AB09-9EF37A295B6EQ33926126-1CC26587-46C4-425D-83C9-A82E35EC58EEQ34036650-A338C254-AA31-4AD6-853F-BF26DC52F032Q34154958-A7B82FC5-D7F9-42F6-BDA5-0FA0679CF627Q34168465-52079637-7B53-4449-85BE-9D67B1455675Q34205905-E7F7E521-26FD-4B4E-84A2-A5C33B3D1979Q34231638-AAAC6D20-53EB-42D5-8F8D-3DBA05DD355AQ34256771-BB0074F9-6998-419B-BC9E-D00896B2E76BQ34382067-C0545443-3CEA-43A7-82F9-22987D8DB136Q34408879-BDBF48E5-E9D4-462C-BFD8-B673176FEA46Q34683065-2F9D5376-1F81-4CEA-972F-23D88224E2A1Q34716864-10C71DCF-0F9D-4952-85AF-56CB955FA400Q34723072-4BF47DF8-CB92-422C-8758-73D676230605Q34753430-3076FBB8-C4A3-4960-89F4-63B69BC34E08Q35020474-E09272C9-7DE7-4E71-A96B-277D1CACC55A
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Hepatitis B e antigen-negative chronic hepatitis B.
@ast
Hepatitis B e antigen-negative chronic hepatitis B.
@en
Hepatitis B e antigen-negative chronic hepatitis B.
@nl
type
label
Hepatitis B e antigen-negative chronic hepatitis B.
@ast
Hepatitis B e antigen-negative chronic hepatitis B.
@en
Hepatitis B e antigen-negative chronic hepatitis B.
@nl
prefLabel
Hepatitis B e antigen-negative chronic hepatitis B.
@ast
Hepatitis B e antigen-negative chronic hepatitis B.
@en
Hepatitis B e antigen-negative chronic hepatitis B.
@nl
P356
P1433
P1476
Hepatitis B e antigen-negative chronic hepatitis B.
@en
P2093
Hadziyannis SJ
Vassilopoulos D
P304
P356
10.1053/JHEP.2001.27834
P407
P433
P577
2001-10-01T00:00:00Z